What research says about microdosing with psilocybin: anxiety, quality of life, and functioning

Microdosing with psilocybin is gaining increasing attention. But what does controlled scientific research actually show? A Ph.D. study conducted at McMaster University by Rotem Petranker is one of the more rigorous attempts to answer that question. Rather than relying solely on self-reports, the study used a double-blind, randomized, placebo-controlled design over a period of eight weeks – the gold standard in clinical research. The findings are nuanced. Let’s take a closer look.

The study: an eight-week trial

Participants diagnosed with Major Depressive Disorder (MDD) received:

• A weekly dose of 2 mg psilocybin (derived from mushroom extract)
• Or a placebo (maltodextrin)

In the first phase, neither participants nor researchers knew who received which substance. In a later phase, participants had the option to switch. This type of design makes it possible to distinguish expectations (placebo effects) from actual pharmacological effects.

The results: not what is often assumed about microdosing

No significant effect on depression scores

On standard measures of depression (such as PHQ-9 and QIDS), no significant difference was found between the psilocybin group and the placebo group. Both groups showed improvement. This may point to a strong placebo effect or the impact of participating in a structured clinical study. Either way, it challenges the idea that microdosing is a direct treatment for depressive symptoms.

Reduced anxiety and improved quality of life

This is where a meaningful difference did emerge. The group receiving psilocybin showed:

• Lower anxiety levels (GAD-7)
• Improvements in overall quality of life (QOLI)

This is a subtler effect, but potentially a more relevant one. Not necessarily feeling better, but functioning differently within how you feel.

A different perspective: psychological flexibility

The researchers interpret these findings partly through the lens of the Acceptance and Commitment Therapy. Microdosing may contribute to:

• Greater psychological flexibility
• Increased willingness to engage with daily life
• The ability to act despite discomfort

The shift, then, is not in removing difficult feelings, but in changing the relationship to them.

Creativity and focus: perception vs. measurement

Many people turn to microdosing for creativity. In this study, it was assessed using objective tasks such as:

• The Unusual Uses Task
• The Remote Associates Test

While participants often reported feeling more creative, objective improvements were less clear and remain subject to further analysis. This highlights something important: what you experience can change before what you can measure does.

What do you notice from a microdose?

An interesting insight from this study is that the classic definition of a microdose may not be entirely accurate. It is often described as “sub-perceptual,” meaning you shouldn’t feel it. In practice, however, many participants were able to tell when they had received psilocybin, simply because they felt subtly different.

At the same time, testing showed that:

• Coordination remained intact
• Functioning was not impaired
• There were no signs of intoxication

A more fitting definition may therefore be: not “imperceptible,” but “non-impairing.”

What does this mean for microdosing?

The conclusion of this study is not black and white. Microdosing does not appear to be a direct treatment for depression, but it may influence anxiety and quality of life – and contribute to a different way of engaging with everyday experience.

At Fungki, this aligns with how we see it: not as a quick fix, but as part of a system. The protocol provides structure. The truffles create movement.

Conclusion

This research adds something meaningful to the conversation. Microdosing is not a magic solution, but it may be a subtle lever. Not necessarily to feel different overnight, but to relate differently to what is already there. And in that shift, small changes can begin to compound.

Read the full study

If you’d like to explore the methodology and results in more detail, you can read the full research by Petranker Rotem 2025 – MICRODOSING PSILOCYBIN OVER EIGHT WEEKS